{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:13:41Z","timestamp":1780553621327,"version":"3.54.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>CLN3 Batten disease (CLN3 disease) is a pediatric lysosomal storage disorder that presents with progressive blindness, motor and cognitive decline, seizures, and premature death. CLN3 disease results from mutations in <jats:italic>CLN3<\/jats:italic> with the most prevalent mutation, a 966\u00a0bp deletion spanning exons 7\u20138, affecting\u2009~\u200975% of patients. Mouse models with complete <jats:italic>Cln3<\/jats:italic> deletion or <jats:italic>Cln3<\/jats:italic><jats:sup><jats:italic>\u0394ex7\/8<\/jats:italic><\/jats:sup> mutation have been invaluable for learning about both the basic biology of CLN3 and the underlying pathological changes associated with CLN3 disease. These models, however, vary in their disease presentation and are limited in their utility for studying the role of nonsense mediated decay, and as a consequence, in testing nonsense suppression therapies and read-through compounds. In order to develop a model containing a disease-causing nonsense point mutation, here we describe a first-of-its-kind <jats:italic>Cln3<\/jats:italic><jats:sup><jats:italic>Q352X<\/jats:italic><\/jats:sup> mouse model containing a c.1054C\u2009&gt;\u2009T (p.Gln352Ter) point mutation. Similar to previously characterized <jats:italic>Cln3<\/jats:italic> mutant mouse lines, this novel model shows pathological deficits throughout the CNS including accumulation of lysosomal storage material and glial activation, and has limited perturbation in behavioral measures. Thus, at the molecular and cellular level, this mouse line provides a valuable tool for testing nonsense suppression therapies or read through compounds in CLN3 disease in the future.<\/jats:p>","DOI":"10.1038\/s41598-020-67478-5","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T10:03:01Z","timestamp":1593424981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A tailored Cln3Q352X mouse model for testing therapeutic interventions in CLN3 Batten disease"],"prefix":"10.1038","volume":"10","author":[{"given":"Logan","family":"Langin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila D.","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Weimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,29]]},"reference":[{"key":"67478_CR1","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1212\/WNL.57.4.576","volume":"57","author":"KE Wisniewski","year":"2001","unstructured":"Wisniewski, K. E., Zhong, N. & Philippart, M. Pheno\/genotypic correlations of neuronal ceroid lipofuscinoses. Neurology 57, 576\u2013581 (2001).","journal-title":"Neurology"},{"key":"67478_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10048-005-0218-3","volume":"6","author":"SE Mole","year":"2005","unstructured":"Mole, S. E., Williams, R. E. & Goebel, H. H. Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses. Neurogenetics 6, 107\u2013126. https:\/\/doi.org\/10.1007\/s10048-005-0218-3 (2005).","journal-title":"Neurogenetics"},{"key":"67478_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41582-019-0138-8","volume":"15","author":"TB Johnson","year":"2019","unstructured":"Johnson, T. B. et al. Therapeutic landscape for Batten disease: current treatments and future prospects. Nat. Rev. Neurol. 15, 161\u2013178. https:\/\/doi.org\/10.1038\/s41582-019-0138-8 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"67478_CR4","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/0092-8674(95)90274-0","volume":"82","author":"Consortium, T. I. B. D","year":"1995","unstructured":"Consortium, T. I. B. D. Isolation of a novel gene underlying Batten disease, CLN3. The International Batten Disease Consortium. Cell 82, 949\u2013957. https:\/\/doi.org\/10.1016\/0092-8674(95)90274-0 (1995).","journal-title":"Cell"},{"key":"67478_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.859","author":"M Mirza","year":"2019","unstructured":"Mirza, M. et al. The CLN3 gene and protein: What we know. Mol. Genet. Genom. Med. https:\/\/doi.org\/10.1002\/mgg3.859 (2019).","journal-title":"Mol. Genet. Genom. Med."},{"key":"67478_CR6","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1016\/j.ymthe.2019.06.015","volume":"27","author":"JT Cain","year":"2019","unstructured":"Cain, J. T. et al. Gene therapy corrects brain and behavioral pathologies in CLN6-Batten disease. Mol. Ther. 27, 1836\u20131847. https:\/\/doi.org\/10.1016\/j.ymthe.2019.06.015 (2019).","journal-title":"Mol. Ther."},{"key":"67478_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary, R. S., Norris, D., Yu, R. & Bennett, C. F. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug Deliv. Rev. 87, 46\u201351. https:\/\/doi.org\/10.1016\/j.addr.2015.01.008 (2015).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"67478_CR8","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","volume":"381","author":"J Kim","year":"2019","unstructured":"Kim, J. et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N. Engl. J. Med. 381, 1644\u20131652. https:\/\/doi.org\/10.1056\/NEJMoa1813279 (2019).","journal-title":"N. Engl. J. Med."},{"key":"67478_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13023-016-0414-2","volume":"11","author":"RD Geraets","year":"2016","unstructured":"Geraets, R. D. et al. Moving towards effective therapeutic strategies for neuronal ceroid lipofuscinosis. Orphanet J. Rare Dis. 11, 40. https:\/\/doi.org\/10.1186\/s13023-016-0414-2 (2016).","journal-title":"Orphanet J. Rare Dis."},{"key":"67478_CR10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41580-019-0126-2","volume":"20","author":"T Kurosaki","year":"2019","unstructured":"Kurosaki, T., Popp, M. W. & Maquat, L. E. Quality and quantity control of gene expression by nonsense-mediated mRNA decay. Nat. Rev. Mol. Cell Biol. 20, 406\u2013420. https:\/\/doi.org\/10.1038\/s41580-019-0126-2 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"67478_CR11","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.molmed.2012.09.008","volume":"18","author":"L Bidou","year":"2012","unstructured":"Bidou, L., Allamand, V., Rousset, J. P. & Namy, O. Sense from nonsense: therapies for premature stop codon diseases. Trends Mol. Med. 18, 679\u2013688. https:\/\/doi.org\/10.1016\/j.molmed.2012.09.008 (2012).","journal-title":"Trends Mol. Med."},{"key":"67478_CR12","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/humu.20763","volume":"29","author":"M Mort","year":"2008","unstructured":"Mort, M., Ivanov, D., Cooper, D. N. & Chuzhanova, N. A. A meta-analysis of nonsense mutations causing human genetic disease. Hum. Mutat. 29, 1037\u20131047. https:\/\/doi.org\/10.1002\/humu.20763 (2008).","journal-title":"Hum. Mutat."},{"key":"67478_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.mrrev.2014.05.001","volume":"762","author":"JN Miller","year":"2014","unstructured":"Miller, J. N. & Pearce, D. A. Nonsense-mediated decay in genetic disease: Friend or foe?. Mutat. Res. Rev. Mutat. Res. 762, 52\u201364. https:\/\/doi.org\/10.1016\/j.mrrev.2014.05.001 (2014).","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"issue":"4","key":"67478_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/diseases4040032","volume":"4","author":"KM Keeling","year":"2016","unstructured":"Keeling, K. M. Nonsense suppression as an approach to treat lysosomal storage diseases. Diseases. 4(4), 32 (2016).","journal-title":"Diseases."},{"key":"67478_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s40259-016-0157-6","volume":"30","author":"K Nagel-Wolfrum","year":"2016","unstructured":"Nagel-Wolfrum, K., Moller, F., Penner, I., Baasov, T. & Wolfrum, U. Targeting nonsense mutations in diseases with translational read-through-inducing drugs (TRIDs). BioDrugs 30, 49\u201374. https:\/\/doi.org\/10.1007\/s40259-016-0157-6 (2016).","journal-title":"BioDrugs"},{"key":"67478_CR16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1006\/nbdi.1999.0267","volume":"6","author":"HM Mitchison","year":"1999","unstructured":"Mitchison, H. M. et al. Targeted disruption of the Cln3 gene provides a mouse model for Batten disease. The Batten Mouse Model Consortium [corrected]. Neurobiol. Dis. 6, 321\u2013334. https:\/\/doi.org\/10.1006\/nbdi.1999.0267 (1999).","journal-title":"Neurobiol. Dis."},{"key":"67478_CR17","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1093\/hmg\/11.22.2709","volume":"11","author":"SL Cotman","year":"2002","unstructured":"Cotman, S. L. et al. Cln3 \u0394ex7\/8 knock-in mice with the common JNCL mutation exhibit progressive neurologic disease that begins before birth. Hum. Mol. Genet. 11, 2709\u20132721. https:\/\/doi.org\/10.1093\/hmg\/11.22.2709 (2002).","journal-title":"Hum. Mol. Genet."},{"key":"67478_CR18","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.bbadis.2013.04.008","volume":"1801\u20131806","author":"A Schulz","year":"1832","unstructured":"Schulz, A., Kohlsch\u00fctter, A., Mink, J., Simonati, A. & Williams, R. NCL diseases\u2014clinical perspectives. Biochim. Biophys. Acta 1801\u20131806, 2013. https:\/\/doi.org\/10.1016\/j.bbadis.2013.04.008 (1832).","journal-title":"Biochim. Biophys. Acta"},{"key":"67478_CR19","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.bbamcr.2008.11.004","volume":"1793","author":"A Jalanko","year":"2009","unstructured":"Jalanko, A. & Braulke, T. Neuronal ceroid lipofuscinoses. Biochim. Biophys. Acta BBA Mol. Cell Res. 1793, 697\u2013709. https:\/\/doi.org\/10.1016\/j.bbamcr.2008.11.004 (2009).","journal-title":"Biochim. Biophys. Acta BBA Mol. Cell Res."},{"key":"67478_CR20","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1093\/hmg\/ddn228","volume":"17","author":"CH Chan","year":"2008","unstructured":"Chan, C. H., Mitchison, H. M. & Pearce, D. A. Transcript and in silico analysis of CLN3 in juvenile neuronal ceroid lipofuscinosis and associated mouse models. Hum. Mol. Genet. 17, 3332\u20133339. https:\/\/doi.org\/10.1093\/hmg\/ddn228 (2008).","journal-title":"Hum. Mol. Genet."},{"key":"67478_CR21","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1242\/jcs.038323","volume":"122","author":"S Codlin","year":"2009","unstructured":"Codlin, S. & Mole, S. E. S. pombe btn1, the orthologue of the Batten disease gene CLN3, is required for vacuole protein sorting of Cpy1p and Golgi exit of Vps10p. J. Cell. Sci. 122, 1163\u20131173. https:\/\/doi.org\/10.1242\/jcs.038323 (2009).","journal-title":"J. Cell. Sci."},{"key":"67478_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1055\/s-2007-973656","volume":"28","author":"HM Mitchison","year":"1997","unstructured":"Mitchison, H. M. et al. Structure of the CLN3 gene and predicted structure, location and function of CLN3 protein. Neuropediatrics 28, 12\u201314 (1997).","journal-title":"Neuropediatrics"},{"key":"67478_CR23","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/bf02191711","volume":"248","author":"K Sugimoto","year":"1995","unstructured":"Sugimoto, K., Matsumoto, K., Kornberg, R. D., Reed, S. I. & Wittenberg, C. Dosage suppressors of the dominant G1 cyclin mutant CLN3-2: identification of a yeast gene encoding a putative RNA\/ssDNA binding protein. Mol. Gen. Genet. MGG 248, 712\u2013718. https:\/\/doi.org\/10.1007\/bf02191711 (1995).","journal-title":"Mol. Gen. Genet. MGG"},{"issue":"Pt 3","key":"67478_CR24","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1042\/bj3340547","volume":"334","author":"DE Sleat","year":"1998","unstructured":"Sleat, D. E., Sohar, I., Pullarkat, P. S., Lobel, P. & Pullarkat, R. K. Specific alterations in levels of mannose 6-phosphorylated glycoproteins in different neuronal ceroid lipofuscinoses. Biochem. J. 334(Pt 3), 547\u2013551 (1998).","journal-title":"Biochem. J."},{"key":"67478_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1006\/nbdi.1999.0267","volume":"6","author":"HM Mitchison","year":"1999","unstructured":"Mitchison, H. M. et al. Targeted disruption of the Cln3 gene provides a mouse model for Batten disease. Neurobiol. Dis. 6, 321\u2013334. https:\/\/doi.org\/10.1006\/nbdi.1999.0267 (1999).","journal-title":"Neurobiol. Dis."},{"key":"67478_CR26","doi-asserted-by":"publisher","first-page":"9592","DOI":"10.1074\/jbc.RA119.008852","volume":"294","author":"C Schmidtke","year":"2019","unstructured":"Schmidtke, C. et al. Lysosomal proteome analysis reveals that CLN3-defective cells have multiple enzyme deficiencies associated with changes in intracellular trafficking. J. Biol. Chem. 294, 9592\u20139604. https:\/\/doi.org\/10.1074\/jbc.RA119.008852 (2019).","journal-title":"J. Biol. Chem."},{"key":"67478_CR27","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/jimd.12106","volume":"42","author":"AP Appu","year":"2019","unstructured":"Appu, A. P. et al. Cln3-mutations underlying juvenile neuronal ceroid lipofuscinosis cause significantly reduced levels of Palmitoyl-protein thioesterases-1 (Ppt1)-protein and Ppt1-enzyme activity in the lysosome. J. Inherit. Metab. Dis. 42, 944\u2013954. https:\/\/doi.org\/10.1002\/jimd.12106 (2019).","journal-title":"J. Inherit. Metab. Dis."},{"key":"67478_CR28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1750-3639.2004.tb00077.x","volume":"14","author":"J Tyynela","year":"2004","unstructured":"Tyynela, J., Cooper, J. D., Khan, M. N., Shemilts, S. J. & Haltia, M. Hippocampal pathology in the human neuronal ceroid-lipofuscinoses: distinct patterns of storage deposition, neurodegeneration and glial activation. Brain Pathol. 14, 349\u2013357 (2004).","journal-title":"Brain Pathol."},{"key":"67478_CR29","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.nbd.2005.05.018","volume":"20","author":"CC Pontikis","year":"2005","unstructured":"Pontikis, C. C., Cotman, S. L., MacDonald, M. E. & Cooper, J. D. Thalamocortical neuron loss and localized astrocytosis in the Cln3Deltaex7\/8 knock-in mouse model of Batten disease. Neurobiol. Dis. 20, 823\u2013836. https:\/\/doi.org\/10.1016\/j.nbd.2005.05.018 (2005).","journal-title":"Neurobiol. Dis."},{"key":"67478_CR30","doi-asserted-by":"publisher","first-page":"14338","DOI":"10.1038\/ncomms14338","volume":"8","author":"M Palmieri","year":"2017","unstructured":"Palmieri, M. et al. mTORC1-independent TFEB activation via Akt inhibition promotes cellular clearance in neurodegenerative storage diseases. Nat. Commun. 8, 14338. https:\/\/doi.org\/10.1038\/ncomms14338 (2017).","journal-title":"Nat. Commun."},{"key":"67478_CR31","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.brainres.2004.07.030","volume":"1023","author":"CC Pontikis","year":"2004","unstructured":"Pontikis, C. C. et al. Late onset neurodegeneration in the Cln3-\/- mouse model of juvenile neuronal ceroid lipofuscinosis is preceded by low level glial activation. Brain Res. 1023, 231\u2013242. https:\/\/doi.org\/10.1016\/j.brainres.2004.07.030 (2004).","journal-title":"Brain Res."},{"key":"67478_CR32","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.neuropharm.2012.05.040","volume":"63","author":"AD Kovacs","year":"2012","unstructured":"Kovacs, A. D. et al. Age-dependent therapeutic effect of memantine in a mouse model of juvenile Batten disease. Neuropharmacology 63, 769\u2013775. https:\/\/doi.org\/10.1016\/j.neuropharm.2012.05.040 (2012).","journal-title":"Neuropharmacology"},{"key":"67478_CR33","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10545-011-9421-6","volume":"35","author":"J Cialone","year":"2012","unstructured":"Cialone, J. et al. Females experience a more severe disease course in Batten disease. J. Inherit. Metab. Dis. 35, 549\u2013555. https:\/\/doi.org\/10.1007\/s10545-011-9421-6 (2012).","journal-title":"J. Inherit. Metab. Dis."},{"key":"67478_CR34","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1242\/dmm.018804","volume":"8","author":"AD Kovacs","year":"2015","unstructured":"Kovacs, A. D. & Pearce, D. A. Finding the most appropriate mouse model of juvenile CLN3 (Batten) disease for therapeutic studies: the importance of genetic background and gender. Dis. Model Mech. 8, 351\u2013361. https:\/\/doi.org\/10.1242\/dmm.018804 (2015).","journal-title":"Dis. Model Mech."},{"key":"67478_CR35","doi-asserted-by":"publisher","first-page":"e0176526","DOI":"10.1371\/journal.pone.0176526","volume":"12","author":"RD Geraets","year":"2017","unstructured":"Geraets, R. D. et al. A tailored mouse model of CLN2 disease: a nonsense mutant for testing personalized therapies. PLoS ONE 12, e0176526. https:\/\/doi.org\/10.1371\/journal.pone.0176526 (2017).","journal-title":"PLoS ONE"},{"key":"67478_CR36","doi-asserted-by":"publisher","first-page":"9117","DOI":"10.1523\/JNEUROSCI.2729-04.2004","volume":"24","author":"DE Sleat","year":"2004","unstructured":"Sleat, D. E. et al. A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration. J. Neurosci. 24, 9117\u20139126. https:\/\/doi.org\/10.1523\/JNEUROSCI.2729-04.2004 (2004).","journal-title":"J. Neurosci."},{"key":"67478_CR37","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.brainres.2009.02.009","volume":"1266","author":"JM Weimer","year":"2009","unstructured":"Weimer, J. M. et al. Cerebellar defects in a mouse model of juvenile neuronal ceroid lipofuscinosis. Brain Res. 1266, 93\u2013107. https:\/\/doi.org\/10.1016\/j.brainres.2009.02.009 (2009).","journal-title":"Brain Res."},{"key":"67478_CR38","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.nbd.2005.11.008","volume":"22","author":"JM Weimer","year":"2006","unstructured":"Weimer, J. M. et al. Visual deficits in a mouse model of Batten disease are the result of optic nerve degeneration and loss of dorsal lateral geniculate thalamic neurons. Neurobiol. Dis. 22, 284\u2013293. https:\/\/doi.org\/10.1016\/j.nbd.2005.11.008 (2006).","journal-title":"Neurobiol. Dis."},{"key":"67478_CR39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1385\/nmm:1:2:111","volume":"1","author":"JM Weimer","year":"2002","unstructured":"Weimer, J. M., Kriscenski-Perry, E., Elshatory, Y. & Pearce, D. A. The neuronal ceroid lipofuscinoses: mutations in different proteins result in similar disease. NeuroMol. Med. 1, 111\u2013124. https:\/\/doi.org\/10.1385\/nmm:1:2:111 (2002).","journal-title":"NeuroMol. Med."},{"key":"67478_CR40","doi-asserted-by":"publisher","first-page":"13566","DOI":"10.1073\/pnas.251485198","volume":"98","author":"P Gupta","year":"2001","unstructured":"Gupta, P. et al. Disruption of PPT1 or PPT2 causes neuronal ceroid lipofuscinosis in knockout mice. Proc. Natl. Acad. Sci. USA 98, 13566\u201313571. https:\/\/doi.org\/10.1073\/pnas.251485198 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67478_CR41","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/hmg\/ddu428","volume":"24","author":"JN Miller","year":"2015","unstructured":"Miller, J. N., Kov\u00e1cs, A. D. & Pearce, D. A. The novel Cln 1(R151X) mouse model of infantile neuronal ceroid lipofuscinosis (INCL) for testing nonsense suppression therapy. Hum. Mol. Genet. 24, 185\u2013196. https:\/\/doi.org\/10.1093\/hmg\/ddu428 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"67478_CR42","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/hmg\/ddh312","volume":"13","author":"O Kopra","year":"2004","unstructured":"Kopra, O. et al. A mouse model for Finnish variant late infantile neuronal ceroid lipofuscinosis, CLN5, reveals neuropathology associated with early aging. Hum. Mol. Genet. 13, 2893\u20132906. https:\/\/doi.org\/10.1093\/hmg\/ddh312 (2004).","journal-title":"Hum. Mol. Genet."},{"key":"67478_CR43","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1177\/0883073813493667","volume":"28","author":"E Kriscenski-Perry","year":"2013","unstructured":"Kriscenski-Perry, E., Kovacs, A. D. & Pearce, D. A. Seizure susceptibility, phenotype, and resultant growth delay in the nclf and mnd mouse models of neuronal ceroid lipofuscinoses. J. Child Neurol. 28, 1137\u20131141. https:\/\/doi.org\/10.1177\/0883073813493667 (2013).","journal-title":"J. Child Neurol."},{"key":"67478_CR44","doi-asserted-by":"publisher","first-page":"e78694","DOI":"10.1371\/journal.pone.0078694","volume":"8","author":"JP Morgan","year":"2013","unstructured":"Morgan, J. P. et al. A murine model of variant late infantile ceroid lipofuscinosis recapitulates behavioral and pathological phenotypes of human disease. PLoS ONE 8, e78694. https:\/\/doi.org\/10.1371\/journal.pone.0078694 (2013).","journal-title":"PLoS ONE"},{"key":"67478_CR45","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1086\/338708","volume":"70","author":"RB Wheeler","year":"2002","unstructured":"Wheeler, R. B. et al. The gene mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein. Am. J. Hum. Genet. 70, 537\u2013542. https:\/\/doi.org\/10.1086\/338708 (2002).","journal-title":"Am. J. Hum. Genet."},{"key":"67478_CR46","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/hmg\/ddv615","volume":"25","author":"L Brandenstein","year":"2016","unstructured":"Brandenstein, L., Schweizer, M., Sedlacik, J., Fiehler, J. & Storch, S. Lysosomal dysfunction and impaired autophagy in a novel mouse model deficient for the lysosomal membrane protein Cln7. Hum. Mol. Genet. 25, 777\u2013791. https:\/\/doi.org\/10.1093\/hmg\/ddv615 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"67478_CR47","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.nbd.2014.01.003","volume":"65","author":"M Damme","year":"2014","unstructured":"Damme, M. et al. Gene disruption of Mfsd8 in mice provides the first animal model for CLN7 disease. Neurobiol. Dis. 65, 12\u201324. https:\/\/doi.org\/10.1016\/j.nbd.2014.01.003 (2014).","journal-title":"Neurobiol. Dis."},{"key":"67478_CR48","doi-asserted-by":"publisher","first-page":"4989","DOI":"10.1167\/iovs.16-20158","volume":"57","author":"W Jankowiak","year":"2016","unstructured":"Jankowiak, W. et al. Retinal degeneration in mice deficient in the lysosomal membrane protein CLN7. Investig. Ophthalmol. Vis. Sci. 57, 4989\u20134998. https:\/\/doi.org\/10.1167\/iovs.16-20158 (2016).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"67478_CR49","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0006-8993(02)02470-8","volume":"937","author":"VJ Bolivar","year":"2002","unstructured":"Bolivar, V. J., Scott Ganus, J. & Messer, A. The development of behavioral abnormalities in the motor neuron degeneration (mnd) mouse. Brain Res. 937, 74\u201382 (2002).","journal-title":"Brain Res."},{"key":"67478_CR50","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/j.1365-2990.2011.01233.x","volume":"38","author":"M Kuronen","year":"2012","unstructured":"Kuronen, M. et al. Galactolipid deficiency in the early pathogenesis of neuronal ceroid lipofuscinosis model Cln8mnd: implications to delayed myelination and oligodendrocyte maturation. Neuropathol. Appl. Neurobiol. 38, 471\u2013486. https:\/\/doi.org\/10.1111\/j.1365-2990.2011.01233.x (2012).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"67478_CR51","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.nbd.2012.04.018","volume":"47","author":"M Kuronen","year":"2012","unstructured":"Kuronen, M., Lehesjoki, A. E., Jalanko, A., Cooper, J. D. & Kopra, O. Selective spatiotemporal patterns of glial activation and neuron loss in the sensory thalamocortical pathways of neuronal ceroid lipofuscinosis 8 mice. Neurobiol. Dis. 47, 444\u2013457. https:\/\/doi.org\/10.1016\/j.nbd.2012.04.018 (2012).","journal-title":"Neurobiol. Dis."},{"key":"67478_CR52","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s12035-012-8248-y","volume":"45","author":"G Traina","year":"2012","unstructured":"Traina, G. et al. Lipofuscin accumulation and gene expression in different tissues of mnd mice. Mol. Neurobiol. 45, 247\u2013257. https:\/\/doi.org\/10.1007\/s12035-012-8248-y (2012).","journal-title":"Mol. Neurobiol."},{"key":"67478_CR53","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1097\/NEN.0b013e318238fc28","volume":"70","author":"S Koch","year":"2011","unstructured":"Koch, S. et al. Morphologic and functional correlates of synaptic pathology in the cathepsin D knockout mouse model of congenital neuronal ceroid lipofuscinosis. J. Neuropathol. Exp. Neurol. 70, 1089\u20131096. https:\/\/doi.org\/10.1097\/NEN.0b013e318238fc28 (2011).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"67478_CR54","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/nen.0b013e31815f3899","volume":"67","author":"S Partanen","year":"2008","unstructured":"Partanen, S. et al. Synaptic changes in the thalamocortical system of cathepsin D-deficient mice: a model of human congenital neuronal ceroid-lipofuscinosis. J. Neuropathol. Exp. Neurol. 67, 16\u201329. https:\/\/doi.org\/10.1097\/nen.0b013e31815f3899 (2008).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"67478_CR55","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1523\/JNEUROSCI.3081-17.2018","volume":"38","author":"AE Arrant","year":"2018","unstructured":"Arrant, A. E., Onyilo, V. C., Unger, D. E. & Roberson, E. D. Progranulin gene therapy improves lysosomal dysfunction and microglial pathology associated with frontotemporal dementia and neuronal ceroid lipofuscinosis. J. Neurosci. 38, 2341\u20132358. https:\/\/doi.org\/10.1523\/JNEUROSCI.3081-17.2018 (2018).","journal-title":"J. Neurosci."},{"key":"67478_CR56","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ajhg.2012.04.021","volume":"90","author":"KR Smith","year":"2012","unstructured":"Smith, K. R. et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am. J. Hum. Genet. 90, 1102\u20131107. https:\/\/doi.org\/10.1016\/j.ajhg.2012.04.021 (2012).","journal-title":"Am. J. Hum. Genet."},{"key":"67478_CR57","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s40478-014-0078-x","volume":"2","author":"Y Tanaka","year":"2014","unstructured":"Tanaka, Y., Chambers, J. K., Matsuwaki, T., Yamanouchi, K. & Nishihara, M. Possible involvement of lysosomal dysfunction in pathological changes of the brain in aged progranulin-deficient mice. Acta Neuropathol. Commun. 2, 78. https:\/\/doi.org\/10.1186\/s40478-014-0078-x (2014).","journal-title":"Acta Neuropathol. Commun."},{"key":"67478_CR58","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1093\/hmg\/ddt057","volume":"22","author":"PJ Schultheis","year":"2013","unstructured":"Schultheis, P. J. et al. Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited \u03b1-synuclein accumulation and age-dependent sensorimotor deficits. Hum. Mol. Genet. 22, 2067\u20132082. https:\/\/doi.org\/10.1093\/hmg\/ddt057 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"67478_CR59","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1128\/MCB.26.6.2309-2316.2006","volume":"26","author":"C-H Tang","year":"2006","unstructured":"Tang, C.-H. et al. Murine cathepsin F deficiency causes neuronal lipofuscinosis and late-onset neurological disease. Mol. Cell. Biol. 26, 2309\u20132316. https:\/\/doi.org\/10.1128\/MCB.26.6.2309-2316.2006 (2006).","journal-title":"Mol. Cell. Biol."},{"key":"67478_CR60","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.expneurol.2009.01.022","volume":"217","author":"SL Macauley","year":"2009","unstructured":"Macauley, S. L. et al. Cerebellar pathology and motor deficits in the palmitoyl protein thioesterase 1-deficient mouse. Exp. Neurol. 217, 124\u2013135. https:\/\/doi.org\/10.1016\/j.expneurol.2009.01.022 (2009).","journal-title":"Exp. Neurol."},{"key":"67478_CR61","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.nbd.2008.06.004","volume":"32","author":"MJ Oswald","year":"2008","unstructured":"Oswald, M. J., Palmer, D. N., Kay, G. W., Barwell, K. J. & Cooper, J. D. Location and connectivity determine GABAergic interneuron survival in the brains of South Hampshire sheep with CLN6 neuronal ceroid lipofuscinosis. Neurobiol. Dis. 32, 50\u201365. https:\/\/doi.org\/10.1016\/j.nbd.2008.06.004 (2008).","journal-title":"Neurobiol. Dis."},{"key":"67478_CR62","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1471-2156-9-83","volume":"9","author":"AB Zetoune","year":"2008","unstructured":"Zetoune, A. B. et al. Comparison of nonsense-mediated mRNA decay efficiency in various murine tissues. BMC Genet. 9, 83. https:\/\/doi.org\/10.1186\/1471-2156-9-83 (2008).","journal-title":"BMC Genet."},{"key":"67478_CR63","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/jcmm.12744","volume":"20","author":"V Thada","year":"2016","unstructured":"Thada, V., Miller, J. N., Kovacs, A. D. & Pearce, D. A. Tissue-specific variation in nonsense mutant transcript level and drug-induced read-through efficiency in the Cln 1(R151X) mouse model of INCL. J. Cell Mol. Med. 20, 381\u2013385. https:\/\/doi.org\/10.1111\/jcmm.12744 (2016).","journal-title":"J. Cell Mol. Med."},{"key":"67478_CR64","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1242\/dmm.018804","volume":"8","author":"AD Kov\u00e1cs","year":"2015","unstructured":"Kov\u00e1cs, A. D. & Pearce, D. A. Finding the most appropriate mouse model of juvenile CLN3 (Batten) disease for therapeutic studies: the importance of genetic background and gender. Dis. Models Mech. 8, 351. https:\/\/doi.org\/10.1242\/dmm.018804 (2015).","journal-title":"Dis. Models Mech."},{"key":"67478_CR65","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402\u2013408. https:\/\/doi.org\/10.1006\/meth.2001.1262 (2001).","journal-title":"Methods"},{"key":"67478_CR66","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13023-019-0994-8","volume":"14","author":"MJ Poppens","year":"2019","unstructured":"Poppens, M. J. et al. Tracking sex-dependent differences in a mouse model of CLN6-Batten disease. Orphanet J. Rare Dis. 14, 19. https:\/\/doi.org\/10.1186\/s13023-019-0994-8 (2019).","journal-title":"Orphanet J. Rare Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67478-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67478-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67478-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T12:54:59Z","timestamp":1670331299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67478-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,29]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["67478"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-67478-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,29]]},"assertion":[{"value":"25 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10591"}}